United States pharmaceutical maker, Pfizer, and biopharmaceutical company, Global Blood Therapeutics (GBT), on Monday, agreed that Pfizer would acquire GBT in an all-cash deal valued at 5.4 billion U.S. dollars.
Pfizer said the acquisition would drive growth by enhancing its work in rare hematology while reinforcing the company’s commitment to sickle cell disease research and treatment.
According to dpa, under the terms of the transaction, Pfizer will acquire all the outstanding shares of California-based GBT for 68.50 dollars per share in cash, for a total enterprise value of approximately 5.4 billion dollars, including debt and net of cash acquired.
READ ALSO: BioNTech, Pfizer to develop vaccine against shingles
The pharmaceutical company expects to finance the transaction with existing cash on hand.
The proposed transaction, unanimously approved by the Boards of Directors of both companies, is subject to customary closing conditions, including receipt of regulatory approvals and approval by GBT’s stockholders.
A police report has reportedly uncovered multiple threats against Argentina captain Lionel Messi during the…
The Federal Government has supplied Benue State with 100 vials of Panaf Premium Anti-Snake Venom…
Troops of the Nigerian Army’s Operation FANAN YANMA, working with personnel of the Mobile Strike…
Troops of Operation FANSAN YANMA, alongside the Nigerian Police Force, have recovered and cleared a…
Atletico Madrid coach Diego Simeone says the club will not allow Argentina forward Julian Alvarez…
The Nigerian Army has held a stakeholders’ security meeting in Riyom Local Government Area of…
This website uses cookies.